Негативные симптомы шизофрении: современные зарубежные концепции и патофизиологические механизмы. Ч. 1
https://doi.org/2618-6667-2018-77-86-96
Аннотация
Данный обзор подготовлен по материалам 25-го конгресса Европейской психиатрической ассоциации (апрель 2017 г., Флоренция) участником проекта «Восточноевропейская академия Всемирной психиатрической ассоциации и компании «Сервье» специально для психиатрических журналов Зоны 10 ВПА (East European Educational WPA — Servier Academy — «EEE WPA-Servier Academy»). Концепция негативных расстройств претерпела существенные изменения в последние годы. Одними из значимых достижений в данной области стала дифференциация негативных расстройств на первичные (связанные с болезненным процессом) и вторичные (связанные с другими причинами, такими как позитивные симптомы, депрессия, побочные эффекты препаратов), а также выделение двух кластеров симптомов: абулии (включая отсутствие мотивации, ангедонию и снижение социальной активности) и снижения экспрессии (включая притупление аффекта и бедность речи), которые могут оказывать различное влияние на функциональные исходы болезни.
Об авторе
Алексей Викторович Павличенко
Московский государственный медико-стоматологический университет им. А.И. Евдокимова, Москва
Россия
Россия
кандидат медицинских наук, доцент, кафедра психиатрии, наркологии
и психотерапии
Список литературы
1. Crow T.J. Positive and negative schizophrenia symptoms and the role of dopamine. The British Journal of Psychiatry. 1981;139(3):251– 254. doi: 10.1192/bjp.139.3.251
2. Mäkinen J., Miettunen J., Isohanni M., Koponen H. Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry. 2008;62(5):334–341. doi: 10.1080/08039480801959307
3. Pogue-Geile M.F., Zubin J. Negative symptomatology and schizophrenia: A conceptual and empirical review. International Journal of Mental Health. 1987;16(4):3–45. doi: 10.1080/00207411.1987.11449074
4. Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Fleischhacker W., for the EUFEST Study Group. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019
5. Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop, P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320
6. Cornblatt B., Obuchowski M. The hillside study of risk and early detection in schizophrenia: Early findings. Schizophrenia Research. 1998;29(1–2):10. doi: 10.1016/s0920-9964(97)88309-0
7. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophrenia Bulletin. 2006;32(2):214–219. doi: 10.1093/schbul/ sbj053
8. Carpenter Jr.W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145(5):578–583. doi: 10.1176/ajp.145.5.578
9. Galderisi S., Färden A., Kaiser S. Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophrenia Research. 2017;186:1–2. doi: 10.1016/j.schres.2016.04.046
10. Buchanan R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophrenia Bulletin. 2007;33(4):1013–1022. doi: 10.1093/ schbul/sbl057
11. Galderisi S., Bucci P., Mucci A., Kirkpatrick B., Pini S., Rossi A., Maj M. Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research. 2013;147(1):157–162. doi: 10.1016/j. schres.2013.03.020
12. Couture S.M., Granholm E.L., Fish S.C. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophrenia Research. 2011;125(2–3):152–160. doi: 10.1016/j. schres.2010.09.020
13. Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287. doi: 10.1002/ wps.20167
14. Strassnig M.T., Raykov T., O’Gorman C., Bowie C.R., Sabbag S., Durand D., Harvey P.D. Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. 2015; 165(1):76–82. doi: 10.1016/j.schres.2015.03.033
15. Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007; Jan;115(1):4–11.
16. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin. 2010;37(2):300–305. doi: 10.1093/schbul/sbq059
17. Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation. American Journal of Psychiatry. 2013;170(2):165–172. doi: 10.1176/appi.ajp.2012.12010109
18. Lyne J., Renwick L., O’Donoghue B., Kinsella A., Malone K., Turner N., Clarke M. Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Research. 2015;228(3):347–354. doi: 10.1016/j.psychres.2015.05.086
19. Kirkpatrick B. Developing concepts in negative symptoms. The Journal of Clinical Psychiatry. 2014;75(suppl. 1):3–7. doi: 10.4088/ jcp.13049su1c.01
20. Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320
21. Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry. 1999;156:406–411.
22. Tandon R., DeQuardo J.R. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 2000;45:191–201.
23. Siris S.G., Addington D., Azorin, J.-M., Falloon I.R., Gerlach J., Hirsch S.R. Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research. 2001;47(2–3):185–197. doi: 10.1016/s0920-9964(00)00135-3
24. Kuck J., Zisook S. Negative symptomatology in schizophrenic outpatients. The Journal of Nervous and Mental Disease. 1992;180(8):510–515. doi: 10.1097/00005053-199208000-00006
25. Lanсon C. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders. 2000; 58(2):107–115. doi: 10.1016/s0165-0327(99)00075-0
26. Siris S.G. Depression in schizophrenia: perspective in the era of «atypical» antipsychotic agents. Am. J. Psychiatry. 2000;157:1379– 1389.
27. Lako I.M., Bruggeman R. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J. Affect. Disord. 2012;140:38–47. doi: 10.1016/j.jad.2011.10.014
28. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. 2008;14(4):429–447. doi: 10.1038/sj.mp.4002136
29. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthøj B., Gattaz W.F. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry. 2015;16(3):142–170. doi: 10.3109/15622975.2015.1009163
30. Pani L., Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Molecular Psychiatry. 2002;7(3):247–253. doi: 10.1038/sj.mp.4001040
31. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B. A., Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2009;36(1):71–93. doi: 10.1093/schbul/sbp116
32. Park C.-H., Park T.-W., Yang J.C., Lee K.-H., Huang G.-B., Tong Z., Chung Y.-C. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol. International Clinical Psychopharmacology. 2012;27(2):114–120. doi: 10.1097/yic.0b013e3283502773
33. Fusar-Poli P., Papanastasiou E., Stahl D., Rocchetti M., Carpenter W., Shergill S., McGuire P. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebocontrolled trials. Schizophrenia Bulletin. 2014;41(4):892–899. doi: 10.1093/schbul/sbu170
34. Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry. 2000;157(9):1461–1466. doi: 10.1176/appi.ajp.157.9.1461
35. Kirschner M., Aleman A., Kaiser S. Secondary negative symptoms: A review of mechanisms, assessment and treatment. Schizophrenia Research. 2017;186:29–38. doi: 10.1016/j.schres.2016.05.003
36. Fervaha G., Takeuchi H., Lee J., Foussias G., Fletcher P.J., Agid O., Remington G. Antipsychotics and amotivation. Neuropsychopharmacology. 2015;40(6):1539–1548. doi: 10.1038/npp.2015.3
37. Takeuchi H., Suzuki T. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. 2013;39:993–998.
38. Oshima I., Mino Y. Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan’s psychiatric hospitals. Psychiatry Res. 2005;136:163–171. doi. org/10.1016/j.psychres.2005.06.001
39. Nordentoft M., Welcher B., Knudsen H.C., Krasnik A., Jessen-Petersen B., Treufeldt P. CCPP-Copenhagen Community Psychiatric Project. Social Psychiatry and Psychiatric Epidemiology. 1996;31(6):336–344. doi: 10.1007/bf00783422
40. Elis O., Caponigro J.M., Kring A.M. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions. Clinical Psychology Review. 2013;33(8):914–928. doi: 10.1016/j.cpr.2013.07.001
41. Rovai L., Maremmani A.G. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv. Psichiatr. 2013;48:1–9. doi: 10.1708/1228.13610
42. Garfield J.B.B., Lubman D.I., Yücel M. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Australian & New Zealand Journal of Psychiatry. 2013;48(1):36–51. doi: 10.1177/0004867413508455.
Рецензия
Для цитирования:
Павличенко А.В. Негативные симптомы шизофрении: современные зарубежные концепции и патофизиологические механизмы. Ч. 1. ПСИХИАТРИЯ. 2018;1(77):86-96. https://doi.org/2618-6667-2018-77-86-96
For citation:
Pavlichenko A. Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1. Psikhiatriya. 2018;1(77):86-96. (In Russ.) https://doi.org/2618-6667-2018-77-86-96
Просмотров: 1790
Послать статью по эл. почте 
